Dosing and administration of recombinant L-asparaginase
AssigneeJazz Pharmaceuticals Ireland Limited
InventorsMi Rim Choi, Tong Lin, Jeffrey Silverman
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for treating a disease treatable by asparagine depletion in a human subject comprising dosing a human subject with L-asparaginase.
Claims20
A method of treating cancer in a human subject in need thereof, said method comprising administering to the human subject L-asparaginase, other than an Escherichia coli derived asparaginase, as a set of time-ordered doses;
- wherein the set of time-ordered doses comprises two series of three doses, wherein a first dose and a second dose are each 25 mg/m2 and a third dose is 50 mg/m2,
- wherein the first, the second and the third dose are administered on a Monday, Wednesday and Friday, respectively, and wherein the L-asparaginase is a tetramer wherein each monomer of the tetramer comprises SEO ID NO:1,
- wherein the doses at 25 mg/m2 are administered intravascularly and the doses at 50 mg/m2 are administered intramuscularly, and
- wherein the cancer is a blood cell cancer treatable by asparagine depletion, thereby treating cancer in the subject.
A method of substituting a treatment of a human subject for cancer, wherein the human subject is in need thereof, said method comprising administering to the human subject, as a substitute for an Escherichia coli derived asparaginase, a series of six doses of an L-asparaginase,
- wherein a first dose and a second dose are each 25 mg/m2 and a third dose is 50 mg/m2,
- wherein the first, the second and the third dose are administered on a Monday, Wednesday and Friday, respectively, and
- wherein the L-asparaginase is a tetramer wherein each monomer of the tetramer comprises SEO ID NO:
- 1
- wherein the doses at 25 mg/m2 are administered intravascularly and the doses at 50 mg/m2 are administered intramuscularly,
- wherein the L-asparaginase is not an Escherichia coli derived asparaginase, and
- wherein the cancer is a blood cell cancer treatable by asparagine depletion, thereby substituting a treatment of the human subject for cancer.
Dependencies are inferred from the claim text.